Nuvation Bio (NUVB) Presents Outcomes from TRUST-II Study

Nuvation Bio Inc. (NYSE:NUVB) is one of the Best Penny Stocks with Huge Upside Potential. On May 27, Nuvation Bio Inc. (NYSE:NUVB) presented new patient-reported outcomes from its TRUST-II study at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026. The presentation was focused on IBTROZI, which treats advanced ROS1-positive non-small cell lung cancer.

​The results presented at the meeting were encouraging, with 88% of patients reporting stability at the first assessment, along with improved quality-of-life scores reaching 93% among patients who had previously been treated with other targeted therapies. Management noted that the improvements held steady across multiple time points throughout treatment.

Moreover, the symptom control was also strong, as around 84% to 96% patients reported stable or improved scores for coughing and shortness of breath, with benefits sustained over eight months. Notably, the FDA approved IBTROZI in June 2025 and has since accepted a supplemental application with updated data. Management noted that the final decision is expected by January 2027.

​Nuvation Bio Inc. (NYSE:NUVB) is an oncology company focused on developing therapies for cancer treatment.

While we acknowledge the risk and potential of NUVB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NUVB and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 9 Most Undervalued Foreign Stocks to Buy Now and 10 Most Undervalued US Stocks According to Hedge Funds. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1